Two-Drug Combo Reverses Aggressive Prostate Cancer Growth

Scientists just found a way to outsmart one of prostate cancer's deadliest survival tricks, and it could save countless lives.

Researchers at the University of Michigan discovered that combining two existing drug types can stop aggressive prostate cancers that evade treatment by literally changing what kind of cells they are. In lab experiments, this double-punch approach dramatically slowed tumor growth and reversed many of the cellular changes that make these cancers so dangerous.

The breakthrough targets a cunning survival mechanism. Most prostate tumors initially respond well to hormone-blocking drugs that cut off their testosterone supply. But some resistant tumors survive by transforming their cellular identity in a process called transdifferentiation. They stop acting like prostate gland cells and become something else entirely.

Dr. Joshi Alumkal, a professor at Michigan Medicine, and his team figured out this transformation has two sides. Cancer cells lose their original glandular characteristics while simultaneously activating stem cell programs that give them a new identity. That dual nature required a dual solution.

The team tested drugs called BET bromodomain inhibitors, which block the pathways cancer cells use to switch identities. These drugs slowed growth but didn't stop it completely. Then they added DNMT inhibitors, which are already FDA-approved for blood cancers. These drugs reactivate genes that get switched off, essentially reminding cancer cells what they used to be.

When researchers used both drugs together, the results surprised even them. The combination suppressed cancer cell growth far more effectively than either drug alone. In mice with implanted prostate tumors, the combination significantly reduced tumor growth at doses much lower than typically recommended, and the animals tolerated the treatment well.

The Bright Side: This discovery offers hope for the roughly one in eight men who will face prostate cancer in their lifetime. Prostate cancer is the second leading cause of cancer death among men in the United States, and nearly all patients with metastatic disease eventually develop resistance to standard treatments. This new approach attacks the problem from both directions at once, preventing cancer cells from both losing their original identity and gaining a dangerous new one.

The research team is now working to identify which patients would benefit most from this treatment combination. They're particularly excited about the possibility of stopping transdifferentiation before it starts, rather than treating it after the fact. Clinical trials are being planned to test whether this drug combination can help patients with treatment-resistant prostate cancer.

The implications could extend far beyond prostate cancer. Similar cellular transformations occur in lung and pancreatic cancers, meaning this two-pronged strategy might work against multiple cancer types.

Sometimes the best solutions come from combining tools we already have in new and smarter ways.